Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases  

作　　者：Giovanni Brandi Michela Venturi Stefania De Lorenzo Francesca Garuti Giorgio Frega Andrea Palloni Ingrid Garajovà Francesca Abbati Gioconda Saccoccio Rita Golfieri Maria Abbondanza Pantaleo Maria Aurelia Barbera 

机构地区：[1]Department of Experimental,Diagnostic and Specialty Medicine,St.Orsola-Malpighi Hospital,Haematological and Oncological Institute,University of Bologna,9 Massarenti street,40138 Bologna,Italy [2]Department of Medical and Surgical Sciences,St.Orsola-Malpighi Hospital,University of Bologna,40138 Bologna,Italy [3]Department of Medicine,Bologna Health Authority,40139 Bologna,Italy [4]Department of Digestive Diseases and Internal Medicine,St.Orsola-Malpighi Hospital,University of Bologna,40138 Bologna,Italy

出　　处：《Cancer Communications》2018年第1期429-435,共7页癌症通讯（英文）

摘　　要：Background:Hepatocellular carcinoma(HCC)is one of the most frequent causes of cancer-related death.Sorafenib,a multitarget angiogenesis inhibitor,is an approved frontline treatment for advanced HCC in Western countries,although a complete response(CR)to treatment is infrequently reported.Capecitabine,an oral fluoropyrimidine,has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib.To date,how-ever,only one case of sustained CR to metronomic capecitabine has been reported.Case presentation:We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained.In the first case,capecitabine was administered as first line therapy;in the second case,capecitabine was used after intolerance to sorafenib;while in the third case,capecitabine was administered after sorafenib failure.Conclusion:Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases.

关 键 词：Hepatocellular carcinoma CAPECITABINE Metronomic capecitabine Complete response SORAFENIB 

分 类 号：R73[医药卫生—肿瘤]